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DOI 10.1016/j.ccr.2011.12.015SUMMARYConstitutive NF-kB activation has causative roles in adult T cell leukemia (ATL) caused by HTLV-1 and other
cancers. Here, we report a pathway involving Polycomb-mediatedmiRNA silencing andNF-kBactivation.We
determine themiRNA signatures and reveal miR-31 loss in primary ATL cells. MiR-31 negatively regulates the
noncanonical NF-kB pathway by targeting NF-kB inducing kinase (NIK). Loss of miR-31 therefore triggers
oncogenic signaling. In ATL cells, miR-31 level is epigenetically regulated, and aberrant upregulation of
Polycomb proteins contribute to miR-31 downregulation in an epigenetic fashion, leading to activation
of NF-kB and apoptosis resistance. Furthermore, this emerging circuit operates in other cancers and
receptor-initiated NF-kB cascade. Our findings provide a perspective involving the epigenetic program,
inflammatory responses, and oncogenic signaling.INTRODUCTION
Adult T cell leukemia (ATL) is an aggressive T cell neoplasm with
very poor prognosis (Yamaguchi and Watanabe, 2002). Human
T cell leukemia virus type I (HTLV-I) is recognized as an etiolog-
ical factor in T cell malignancy. Although mounting molecular
evidence has contributed to our ability to cure several cancers
and other diseases, the genetic background of ATL leukemogen-
esis is not yet fully understood. Thus, it is an urgent request to
clarify the molecular mechanism of ATL development.
Constitutive activation of nuclear factor-kB (NF-kB) is
observed in the ATL cell lines and primary isolated tumor cells
from ATL patients, although the viral oncoprotein Tax, a powerful
activator of NF-kB, is not expressed in these malignant cellsSignificance
Here, we propose a molecular perspective of the onset of onco
for constitutive NF-kB activation in various types of cancers. U
miR-31 as a suppressor of NIK that is completely silenced in A
Polycomb is implicated in NF-kB signaling via miRNA regula
Polycomb-mediated epigenetic regulation and the NF-kB sig
NF-kB to epigenetic reprogramming.
C(Hironaka et al., 2004; Watanabe et al., 2005). NF-kB activation
aberrantly contributes to cell propagation and anti-apoptotic
responses in ATL and other cancers (Prasad et al., 2010). In
our previous study, inhibition of NF-kB activity with a specific
inhibitor, DHMEQ, drastically impaired the levels of ATL cell
growth and resistance to apoptosis (Watanabe et al., 2005),
suggesting that the molecular background of aberrant NF-kB
activation may give us potential therapeutic targets. A recent
report provided a new readout that NF-kB-inducing kinase
(NIK) has a causal role in tumor progression and the aggressive
phenotypes of various cancers, including ATL (Saitoh et al.,
2008). NIK plays a pivotal role in the noncanonical (alternative)
NF-kB pathway as a crucial kinase in receptor-initiating
signaling, including signaling from CD40, LTBR, and BAFFR.genic signaling. NIK overexpression is a major driving force
sing ATL cells as a model of NF-kB-addiction, we identified
TL cells. Furthermore, an oncogenic function of a subset of
tion. This study introduces a fundamental link between the
naling, allowing us to attribute the constitutive activation of
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significance of NIK protein in epithelial cell proliferation, inflam-
matory response, and oncogenic signaling (for review, see Thu
and Richmond, 2010). Although the expression level of NIK is
strictly maintained by proteasomal degradation in normal cells
(Liao et al., 2004), increased level of NIK transcript are observed
in some cancers, causing inappropriate accumulation of NIK
protein without stimuli (Annunziata et al., 2007; Saitoh et al.,
2008). Overexpression of NIK leads to aberrant phenotypes in
several cell types; however, little is known about the abnormal
accumulation of NIK in malignant cells.
Recent advances have led to deeper understanding of a new
aspect of posttranscriptional gene regulation, i.e., regulation by
a class of noncoding RNAs. MicroRNAs (miRNAs) are functional
RNAs with 18–25 nt in length that contribute to a class of cellular
functions by negatively controlling targeted gene expression via
base-pairing to 30 untranslated region (30 UTR). A single miRNA
regulates the expression of multiple genes, and the functions of
miRNAs therefore need to be orchestrated for cellular homeo-
stasis (Ventura and Jacks, 2009). In the context of cancer
pathology, many studies have provided evidences that miRNAs
can act as either oncogenes or tumor suppressors. Although the
relationship between miRNA deregulation and oncogenes has
been clarified in several cancer cells, there has been no inte-
grated analysis of gene expression in ATL. Since miRNAs
have important functions in living cells, miRNA expression
needs to be tightly regulated. Our knowledge about the regula-
tory mechanisms of miRNA expression is very inadequate
because research effort has focused mainly on the role of
miRNAs, which remains one of the most intriguing questions.
miRNA regulation involves multiple steps. miRNA maturation
has been identified as an important step, and its deregulation
leads to progression and development of cancer (Davis et al.,
2008; Trabucchi et al., 2009). Genetic deletion in cancer cells
has also been reported to account for specific miRNA defect
(Varambally et al., 2008). In addition, miRNA expression seems
to be epigenetically programmed. DNA methylation and histone
modification are strong candidates for miRNA regulation and
their abnormalities, therefore, have causal roles in cancer initia-
tion, development, and progression. In particular, Polycomb
group proteins have central functions in cellular development
and regeneration by controlling histone methylation, especially
at histone H3 Lys27 (H3K27), which induces chromatin
compaction (Simon and Kingston, 2009). Recent studies have
revealed that the amount of Polycomb family is closely associ-
ated with cancer phenotypes and malignancy in breast cancer,
prostate cancer, and other neoplasms (Sparmann and van Lo-
huizen, 2006). However, the substantial status of Polycomb
family and their epigenetic impact in ATL cells have not been
documented. Furthermore, the general roles of Polycomb
proteins in miRNA regulation are mostly unknown. As described
above, since miRNAs are multifunctional molecules in gene
regulation, it is of pivotal importance to clarify the miRNAs
functions and their regulatory circuit in order to formulate
therapeutic strategies.
In the present study, we first performed global miRNA and
mRNA profilings of the ATL cells derived from patients to
precisely define the significance of miRNA expressions and
functions.122 Cancer Cell 21, 121–135, January 17, 2012 ª2012 Elsevier Inc.RESULTS
miRNA Expression Signature in Primary ATL Cells
To characterize the miRNA expression signature in the primary
ATL cells, we first performed an miRNA expression microarray
analysis. For results with physiological significance, we used
total RNA prepared from clinical ATL samples (n = 40, Table
S1 available online) and control CD4+ T cells from healthy donors
(n = 22) aged 50–70 years. A strict threshold (p < 1 3 105) and
two-dimensional hierarchical clustering analysis revealed 61
miRNAs that showed significantly altered levels of expression
in ATL cells compared with those of control CD4+ T cells (Fig-
ure 1A). It is noteworthy that 59 miRNAs out of 61 (96.7%)
showed decreased expression in the primary ATL cells. Among
them, we identified miR-31 as one of the most profoundly
repressed miRNAs in all ATL individuals (fold change, 0.00403;
Figure 1B). miR-31 was recently reported as a tumor suppressor
and/or metastasis-associated miRNA in metastatic breast
cancer. However, the biological functions of miR-31 in lympho-
cytes have not been studied. We therefore focused on the
biological significance and regulatory mechanisms of miR-31
expression in T cells as well as in solid cancers.
miR-31 Negatively Regulates NF-kB Signaling
via NIK Expression
To study the functional significance of miR-31 loss, we attemp-
ted to identify the target genes of miR-31 using four computa-
tional algorithms. We also performed gene expression microar-
ray analysis of the primary ATL cells (n = 52, Table S1) and
normal CD4+ T cells (n = 21) in order to detect aberrations in
gene expression. Selected putative target genes are known to
be involved in cell-cycle regulation and T cell development (Table
S2). To experimentally identify the target genes, we performed
reporter-based screens as described below. Luciferase-30 UTR
reporter assays demonstrated a remarkable negative effect
against upstream gene expression by the MAP3K14 30 UTR
sequence (Figure S1B), which is consistent with an initial cloning
report (Malinin et al., 1997). MAP3K14, also known as NIK, has
a central role in noncanonical NF-kB signaling by phosphoryla-
tion of IKKa. A previous report (Saitoh et al., 2008) and the
present results (Table S2) show that NIK is overexpressed in
ATL cells, leading to constitutive NF-kB activation. As shown in
Figure 2A, treatment with a miR-31 inhibitor increased NIK 30
UTR reporter activity, suggesting the involvement of endoge-
nous miR-31 in NIK downregulation. A computational search
predicted one site each of miR-31 and miR-31 antisense
(miR-31*) binding sites in the NIK 30 UTR (Figure 2B). To identify
the regulatory sequence in 30 UTR of NIK, we established addi-
tional two reporters with mutated sequence in each potential
seed region (Figure 2C; Figure S1C). Mutant 1, which contains
mutated sequence in the miR-31 seed region, partially canceled
the negative effect of endogenous miR-31 (Figure S1D) and
prevented the effect of Anti-miR-31 treatment (Figure 2D).
On the contrary, our results suggest that miR-31* does not
participate in NIK regulation. miR-31-mediated reporter regula-
tion was also observed in T cell lines (Figure S1E). To confirm
the results, we repeated the experiment to examine whether
miR-31 could inhibit NIK expression through seed sequence.
We made expression plasmid vectors carrying NIK, NIK-30
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Figure 1. Global Profiling of Cellular miRNA on Primary ATL Cells
(A) Two-dimensional hierarchical clustering analysis and Pearson correlation as similarity measure on the miRNAs expressed at significantly different levels
between the ATL (n = 40) and the control (n = 22) groups. Sixty-one miRNAs were identified (p < 13 105) and by filtering on more than 5-fold changes. A vertical
branch shows the expression pattern of the selected miRNAs in each individual.
(B)Foldchanges in the61miRNAsbetweenATLandNormal (p<105, fold change>5-fold). SelectedmiRNAsarearrangedaccording topvalues.SeealsoTableS1.
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Epigenetic Loss of miR-31 Activates NF-kBUTRWT, or NIK-30 UTRMu1 and tested their expressions in 293T
cells. Results demonstrated that expression of NIK-30 UTRWT
was inhibited by simultaneous introduction ofmiR-31 (Figure 2E).
miR-31 inhibition inversely rescued the NIK level, revealing that
the cellular miR-31 level negatively affected that of the NIK
protein through its 30 UTR sequence. These lines of evidence
collectively demonstrated that miR-31 recognizes and regulates
NIK mRNA through specific binding to its 30 UTR.CTransient introduction of the miR-31 precursor in TL-Om1
cells, which were established from an ATL patient, resulted in
downregulation of NIK at the mRNA and protein levels, associ-
ated with downregulation of the phospho-IKKa/b level and
NF-kB activity (Figures S1F and S1G). In contrast, miR-31 inhibi-
tion resulted in accumulation of NIK mRNA and protein in HeLa
cells (Figure 2F). Manipulation of the miR-31 level clearly indi-
cated that the miR-31 level negatively correlates with cellularancer Cell 21, 121–135, January 17, 2012 ª2012 Elsevier Inc. 123
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Figure 2. miR-31 Is a Negative Regulator of NF-kB Pathway by Inhibiting NIK Expression
(A) Reporter-basedmiR-31’s target gene screening. A series of 30 UTR-luciferase reporters was transfected in HeLa cells together with or without miR-31 specific
inhibitory RNA (Anti-miR-31) or control RNA (Anti-control). Relative values of Dual-luciferase assay are presented. ‘‘Non-target’’ represents reporter without any
30 UTR. ‘‘di-miR-31’’ reporter contains two perfect match sequences. The data are presented as mean ± SD of three independent experiments.
(B) Schematic of miR-31 target sites in the NIK 30 UTR.
(C) Mutation-induced reporters. Red box stands for mutated target region (see Figure S1C).
(D) miR-31 negatively regulates NIK 30 UTR analyzed by reporter assay (n = 4, mean ± SD). Luciferase activities of reporter series were tested in a presence or
absence of miR-31 inhibitor.
(E) FLAG-tagged NIK protein is negatively regulated through its 30 UTR and miR-31 binding. Plasmid vectors and miR-31 precursor or miR-31 inhibitor are
cotransfected in 293T cells. Western blots showed levels of NIK and endogenous p52. Asterisk indicates nonspecific bands.
(F) NIK mRNA (left) and protein (right) levels in HeLa cells measured by quantitative RT-PCR (n = 3, mean ± SD) and western blotting, respectively. Treatment of
miR-31 inhibitor resulted in NIK accumulation. Result of densitometry is shown in the bottom panel. Asterisk indicates nonspecific bands.
(G) Cellular NF-kB activity in HeLa cells (n = 5, mean ± SD) in a presence or absence of miR-31 precursor or inhibitor.
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Epigenetic Loss of miR-31 Activates NF-kBNF-kB activity (Figure 2G). Furthermore, enforced miR-31
expression in B cells attenuated both BAFF and CD40L-medi-
ated NIK accumulation and the subsequent NF-kB signaling
(Figures 2H–2K). Consistent with previous reports (Ramak-
rishnan et al., 2004; Zarnegar et al., 2008b), we also found
decreased levels of IkBa phosphorylation. On the other hand,
TNF-a-triggered canonical NF-kB activation was not affected
by miR-31 in Jurkat cells (Figures S1H–S1K). These results
collectively show that miR-31 inhibits the basal and receptor-
initiated activities of noncanonical NF-kB pathway. With genetic
evidence and an experimental approach, we further demon-
strated that the function of miR-31 is well conserved among
several classes of species (Figures S1L–S1O). Taking together
all these results, miR-31, which is almost completely absent
in primary ATL cells, appears to play a critical role in negative
regulation of the NF-kB pathway by manipulating the expression
of NIK.
miR-31 Suppresses ATL Cell Growth and Promotes
Apoptosis by Inhibiting NF-kB
Although it was documented that abnormal NIK accumulation in
ATL cells acts as a constitutive activator of the NF-kB pathway,
the mechanism underlying overproduction of NIK remains to be
elucidated. The results described in the previous section indi-
cated that the amount of miR-31 is linked to the level of NIK,
and we therefore speculated that downregulation of miR-31
expression is at least partially responsible for the constitutive
activation of NF-kB in ATL cells. Quantitative RT-PCR revealed
that NIK mRNA levels were negatively correlated with miR-31
levels in primary ATL cell samples (Figure 3A). To investigate
the functional roles of NIK and miR-31, we established TL-
Om1 cells stably expressing the miR-31 or NIK specific shRNA
(shNIK) by retroviral vectors. RT-PCR and western blots showed
that expression of miR-31 or shNIK reduced NIK at mRNA and
protein levels as well as the levels of phospho-IKKa/b, p52,
and IkBa (Figures 3B and 3C). Decreased levels of nuclear
RelA and RelB are considered to represent repressed activities
of the canonical and noncanonical NF-kB pathways, respec-
tively (Figure 3D). EMSA and NF-kB reporter assays also
revealed the repressive function of miR-31 and shNIK on the
NF-kB activity (Figures 3E and 3F; Figures S2A, S2B, S5B, and
S5C). Re-expression of NIK led to NF-kB activation that was
inhibited by miR-31, suggesting a reciprocal relationship
between the level of miR-31 and that of NIK.
We and others previously showed that constitutive NF-kB
activation is a strong driver of ATL proliferation and prosurvival
properties. Here, we examined the effects of miR-31 loss on
ATL cell growth. We found that TL-Om1 cells expressing
miR-31 or shNIK showed a significant attenuation of cell prolifer-
ation compared with control cells. In addition, serum starvation
experiments showed greater sensitivity to induced cell death in
NIK-repressed cells (Figure 3G). miR-31 expression showed
the same phenotypic results in other ATL-derived cell lines(H–K) miR-31 attenuates signal-dependent NF-kB activation in B cells. (H and I) B
or CD40L (0.5 mg/ml) for indicated time periods. The protein levels of NIK, phosph
shown. Actin was detected as control. (J) NF-kB activity (n = 5, mean ± SD) evalu
NF-kB-dependent gene expressions were inhibited by miR-31 (n = 3, mean ± SD
C(Figures S2C, S2D, and S5E). Jurkat cells do not have significant
basal activity of NF-kB, and showed no significant difference
in cell growth with or without induced expression of miR-31
(Figure S2E).
Next, we hypothesized that miR-31-mediated NF-kB modula-
tion may affect cellular apoptosis, because numerous studies
have demonstrated that NF-kB activation is a strong antiapop-
totic factor in ATL and other cancer cells. We found that repres-
sion of NIK by miR-31 or shNIK resulted in downregulation of
a subset of genes involved in resistance to apoptosis such as
BCL-XL, XIAP, and FLIP (Figure 3H), suggesting that miR-31
has a role in proapoptosis through inhibition of NF-kB activity.
To assess the biological function of miR-31 in apoptosis signals,
we utilized a lentivirus gene transfer system for cell lines and
freshly isolated tumor cells. The lentivirus vector is competent
to infect nondividing cells and the infected cells can be moni-
tored by the fluorescence of Venus. We found that lentivirus-
mediated miR-31 expression promoted basal and Fas-directed
apoptosis in TL-Om1 cells (Figure 3I). Venus-negative population
showed no significant changes, demonstrating the specificity of
miR-31 activity. To confirm the relationship among miR-31, NIK,
and NF-kB signaling, we also prepared another retroviral vector
encoding NIKwithout its 30 UTR sequence. As results, re-expres-
sion of NIK reversed the miR-31-mediated apoptosis. In addi-
tion, miR-31 expression led to caspase 3 activation (Figure 3J).
Collectively, these findings indicate that miR-31 mediates
apoptosis through repression of NIK in ATL cell lines.
Tumor cells from ATL patients primarily represent the malig-
nant characteristics. In fact, miR-31 loss is found from patient
samples (Figures 1 and 3A). To demonstrate the responsibility
of miR-31 for tumor cell survival, we tested whether lentivirus-
mediated miR-31 expression has a killing effect against tumor
cells. After establishment of lentivirus infection, the apoptotic
cells were determined by flow cytometry. The results revealed
that expression of miR-31 facilitated tumor cell death. Since
NIK repression by shRNA lentivirus also showed a strong killing
effect, NIK and NF-kB activity are suggested as crucial players
for survival in ATL tumor cells (Figure 3K). Strong toxicities
were not observed in normal resting lymphocytes that express
low levels of NIK. Taken together, these lines of experimental
evidence, including data from cell lines and primary ATL cells,
definitively support two notions that (1) miR-31 acts as a tumor
suppressor in T cells, and (2) NIK-regulated NF-kB has pivotal
importance in cancer cell survival.
Loss of miR-31 Occurs in T Cells with Genetic
and Epigenetic Abnormalities
The results described above together with previous publications
indicate that regulation of miR-31 expression has profound
impacts on multiple functions in human tumors as well as in
normal cells. However, little is known about the regulatory
mechanism of miR-31 expression. The human gene that
encodes miR-31, hsa-miR-31, is located at 9p21.3, which isJAB cells expressing miR-31 or control RNA were treated with BAFF (0.2 mg/ml)
o-IKKa/b, p100/p52 (arrowheads indicate active p52), and phospho-IkBawere
ated by NF-kB-luciferase reporter assay at 24 hr after cytokine treatments. (K)
). See also Table S2 and Figure S1.
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Figure 3. Loss of miR-31 Is Responsible for Constitutive NF-kB Activation, Abnormal Cell Growth, and Resistance to Apoptotic Cell Death in
ATL Cells
(A) Expression levels of miR-31 and NIK in individual ATL patients and normal controls using data set obtained by quantitative RT-PCR. Pearson’s correlation
coefficient within ATL samples was described in the graph.
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Epigenetic Loss of miR-31 Activates NF-kBadjacent to clusters of the CDKN2 and IFNA families, and is
a well-known hotspot of genomic loss in several types of human
cancers.We performed genome-wide scans of genetic lesions in
168 ATL samples and demonstrated that 21 ATL cases (12.5%)
had genomic deletion of 9p21.3 containing the hsa-miR-31
coding region (Figure 4A; Figure S3A). All of these cases also
have genomic defect in CDKN2A region. A major proportion of
ATL cases that are without genetic deletion and somatic muta-
tion in the hsa-miR-31 region showed remarkable loss of miR-
31 expression (Figure 4B). Detailed expression profiling revealed
drastic downregulation of Pri-miR-31 transcription in the primary
ATL cells (Figure 4C). There was a strong correlation between
the levels of mature miR-31 and primary transcript (r = 0.9414,
p = 5.45 3 108). hsa-miR-31 is located in intronic region of
LOC554202 gene. However, LOC554202 mRNA levels were
very low in primary T cells and there was no significant difference
between ATL and normal cells, strongly suggesting that loss of
miR-31 expression is due to specific transcriptional suppression
in ATL cells. Using computational analysis, we identified
a putative TATA box and transcriptional start site (TSS) 2500 bp
upstream of the miR-31 coding region (Figure 4D). Although no
CpG islands were found in this region, we unexpectedly discov-
ered an assembly of YY1-binding motifs upstream of the miR-31
region in human and mouse (Figure 4D; Figure S3C). YY1 is
a pivotal transcription factor and a recruitor of the Polycomb
repressive complex (PRC) (Simon and Kingston, 2009). Conver-
gence of the YY1 binding sequence, especially the repressive
motif (Figure S3D), seems to be evolutionarily conserved,
suggesting that YY1 is important in the regulation of miR-31 tran-
scription. We further performed chromatin immunoprecipitation
(ChIP) to evaluate repressive histone hallmarks, including
di- and trimethylated H3K9 (H3K9me2 and H3K9me3) and trime-
thylated H3K27 (H3K27me3). The results showed higher levels of
methylation at H3K9 and H3K27 in a broad area containing the
miR-31 coding region (Figure 4E). As shown in Figures S3E–
S3G, there was an inverse correlation between the levels of
miR-31 expression and repressive histone methylation. These
data allowed us to hypothesize that histone methylation, espe-
cially that of Polycomb family-dependent H3K27me3, may
contribute to miR-31 repression. To confirm our hypothesis,
we performed a YY1 knockdown experiment using a specific
shRNA (Figures 4F–4I). As expected, knockdown of YY1 led to
an increase in the levels of Pri-miR-31 and mature miR-31
(Figures 4F and 4G). Furthermore, ChIP assays showed that(B) miR-31 restoration by retroviral vector inhibits NIK RNA accumulation in TL-Om
mean ± SD).
(C) miR-31 or shNIK expression downregulates NIK protein expression and inhib
(D) Reduced nuclear translocation of RelA and RelB proteins in miR-31- or shNIK
(E) miR-31-dependent downregulation of NF-kB activity in TL-Om1 cells examin
(F) NF-kB-luciferase reporter assays (n = 5, mean ± SD). FLAG-NIK plasmid was
(G) miR-31 level is relevant to proliferation of ATL cells. Cell proliferation curve o
(H) Apoptosis-related gene expression in TL-Om1 cells analyzed by qRT-PCR (n
(I) Lentivirus-mediated NIK depletion promotes basal and Fas antibody-mediate
Apoptotic cells were determined by PE-Annexin V / 7-AAD stainings (n = 4). Rep
(J) miR-31 activates Caspase 3/7 determined by FACS (n = 3).
(K) miR-31 expression and NIK depletion induce tumor cell death. Primary tumor
analyzed by FACS. The apoptotic cells were defined by sequential gating beginnin
population, and calculating the PE-Annexin V and 7-AAD profilings. Representat
Figure S2.
CYY1 occupied the miR-31 region, especially in the upstream
region of TSS, where there is an array of YY1 binding sites
(Figures 4D and 4H). The results also demonstrated that
decreased occupancy of YY1 and concomitant derecruitment
of EZH2, a key component of PRC2, were induced by YY1
knockdown, indicating involvement of EZH2 in the repressive
complex recruited to the miR-31 region (Figures 4H and 4I; Fig-
ure S3H). These results collectively suggest that YY1 regulates
PRC2 localization and initiates miR-31 suppression. Indeed,
we found significant escalation of methylated histone H3K9
and H3K27 at the miR-31 locus of peripheral blood lymphocytes
of ATL patients (Figure 4J), indicating that aberrant abundance of
suppressive histone methylation may be responsible for the loss
of miR-31 in the primary ATL cells.
Overexpression of PRC2 Components Leads to miR-31
Repression
Given that Polycomb-mediated repressiveness affects miR-31
level, our findings imply that the amount of EZH2 is related to
miR-31 expression (Figure 4I; Figures S3G and S4A). We found
a significantly upregulated expression of PRC2 components,
especially EZH2 and SUZ12, in the primary ATL cells (Figures
5A and 5B; Table S3). Quantitative RT-PCR revealed that miR-
31 levels inversely correlated with both EZH2 and SUZ12,
respectively (Figure 5C). miR-101 and miR-26a, which are puta-
tive negative regulators of EZH2, seem to be associated with this
relationship in ATL cells (Figures S4B–S4E). To further confirm
our hypothetical mechanism linking the epigenetic machinery
and miR-31 expression, we performed a ‘‘loss-of-PRC2-func-
tion’’ assay. Retroviral delivery of shSUZ12 and shEZH2 in the
ATL cell lines resulted in a great increase in the levels of
Pri-miR-31 and its mature form (Figure 5D; Figure S4F). Knock-
down of PRC2 induced histone demethylation at H3K27 in the
miR-31 region, which is concomitant with the decrease in
H3K9me3 levels, EZH2 occupancy, and HDAC1 recruitment
(Figure 5E), suggesting that this multimeric complex leads to
a completely closed chromatin architecture as a result of histone
modifications in the miR-31 genomic region.
To further examine whether the proposed mechanism holds
true in other human cancers, we analyzed a couple of carcinoma
cell lines, including HeLa cells and nonmetastatic andmetastatic
breast carcinoma cell lines, MCF7 and MDA-MB-453 cells,
respectively. qRT-PCR revealed that expression of EZH2 and
SUZ12 inversely correlated with miR-31 levels (Figure S4G).1 cells. The results ofNIK andmature miR-31 quantifications are shown (n = 3,
its downstream pathway of noncanonical NF-kB in TL-Om1 cells.
-expressing TL-Om1 cells.
ed by EMSA.
transiently introduced 48 hr prior to the assay.
f TL-Om1 cells were evaluated in two FCS conditions (n = 3, mean ± SD).
= 3, mean ± SD) and western blots.
d apoptosis. Venus-positive population represented lentivirus-infected cells.
resentative FACS analyses are shown.
cell from ATL patient and healthy CD3+ T cells were infected with lentivirus and
g with FSC-SSC to select intact lymphocytes, subgating on the Venus-positive
ive result is shown and summarized data are presented in Figure 6J. See also
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Cancer Cell
Epigenetic Loss of miR-31 Activates NF-kBChIP assays detected higher levels of trimethylated H3K27 and
EZH2 occupancy in cells showing lower expression levels of
miR-31 (Figure S4H). Furthermore, knockdown of EZH2 or
SUZ12 restored miR-31 transcription in MDA-MB-453 and
MCF7 cells (Figures 5F and 5G; Figure S4K, respectively), which
are consistent with the results obtained with ATL cells. These
results indicate a link between Polycomb-mediated epigenetic
regulation and miR-31 transcription in ATL and breast cancer
cell lines.
Polycomb Group Regulates NF-kB Pathway
by Controlling miR-31 Expression
Based on our findings, we considered an aspect of the biological
communication between epigenetic silencing and the NF-kB
pathway through miR-31 regulation. The microarray data sets
showed positive correlations between PRC2 components and
miR-31 target gene, NIK expression (Figure 6A). The results
also suggested that these factors tend to show higher levels in
the aggressive subtype (acute type) than in the indolent subtypes
(chronic and smoldering types), implying that these genes may
play important roles in the clinical phenotype and prognosis of
ATL. To examine this notion, we performed PRC2 knockdown
in ATL cell lines. Western blots of these cells demonstrated
decreased levels of NIK, p52, and phospho-IkBa (Figure 6B; Fig-
ure S5A), suggesting suppression of both canonical and nonca-
nonical NF-kB cascade and activity (Figure 6C; Figures S5B and
S5C). These results are consistent with those of miR-31 overex-
pression (Figures 3C–3F). Then, we tested whether exogenous
manipulation of miR-31 could restore the effect of PRC2 loss.
Anti-miR-31 treatment rescued impaired NF-kB activity in
PRC2-disrupted cells (Figure 6D). On the other hand, overex-
pression of EZH2 induced NF-kB activation, which was partially
canceled by the introduction ofmiR-31 precursor (Figure 6E; Fig-
ure S5D). These results suggest that Polycomb-mediated miR-
31 suppression leads to NF-kB activation. Indeed, knockdown
of the PRC2 complex led to reduced levels of cell proliferation
and greater sensitivity to serum deprivation in ATL cells (Fig-
ure 6F; Figure S5E). In addition, PRC2 disruption showed
a reduction in cell migration (Figure S5F).
To gain further insight into this general network, we studied
the functions of miR-31 and the PRC2 complex in breast cancer
cell lines. NF-kB activity was downregulated by knockdown ofFigure 4. Genetic and Epigenetic Abnormalities Cause miR-31 Loss in
(A) Genomic loss of chromosome 9p21.3 in primary ATL cells. Copy number analy
region (46/168). Recurrent genetic changes are depicted by horizontal lines base
(B) miR-31 expression in various sample sets. Expression levels were evaluated
Loss, samples with genomic loss of the miR-31 region; () samples without gen
(C) PCR-based miR-31 quantifications in primary ATL samples. ATL samples with
(n = 7) were tested. p values (ATL versus normal) are shown.
(D) YY1 binding motif cluster around transcriptional start site (TSS) of miR-31 reg
ChIP assay are shown.
(E) Repression-associated histone methylation in miR-31 region determined by C
control are presented and distance from miR-31 TSS is described. MYT1 and G
(F–I) YY1-dependent EZH2 occupancy inmiR-31 locus. (F) YY1 knockdown in TL-
decreased YY1 level. (G) YY1 knockdown led to both primary and mature miR-31
region analyzed by ChIP (n = 3, mean ± SD). YY1 occupancy in miR-31 locus was
ChIP (n = 3, mean ± SD). YY1 knockdown inhibited EZH2 recruitment in miR-31
(J) Aberrant accumulation of repression-associated histone methylations widely in
(n = 6) were analyzed by ChIP assay. PBMC from healthy adults were used for n
CPRC2 components in MDA-MB-453 cells (Figure 6G; Figures
S5G and S5H), although no significant differences were
observed in cell proliferation (data not shown). Repression of
NF-kB activity induced by knockdown of PRC2 components
was partially restored by treatment with a miR-31 inhibitor, sug-
gesting that PRC2 knockdown-mediated relief of NF-kB repres-
sion is at least a part of the result of the miR-31 induction. In
addition, knockdown of PRC2 components resulted in a reduced
level of receptor-initiated accumulation of NIK in B cells (Fig-
ure 6H). Our findings indicate a common molecular mechanism
comprising Polycomb-mediated epigenetic regulation, miR-31
expression and the NF-kB signaling pathway.
Regulation of NF-kB by Polycomb family may in turn control
the cellular apoptosis responses. We found that lentivirus-medi-
ated EZH2 knockdown led to increased apoptotic sensitivity in
TL-Om1 cells (Figure 6I). Additional expression of NIK inhibited
the cell death induced by EZH2 knockdown, suggesting the
reciprocal relationship between Polycomb andNF-kB cascades.
By using primary tumor cells from patient, we tested the killing
effect induced by miR-31, NIK knockdown, and EZH2 knock-
down (Figure 6J; Figures S5I and S5J). All tested samples
showed strong death response, demonstrating that survival of
ATL cells was closely associated with miR-31, NIK, and EZH2,
all of which show deregulated expression in ATL cells.
By qRT-PCR we finally examined the expression levels of
some genes involved in the noncanonical NF-kB pathway. As
shown in Figure 6K, the results clearly demonstrated higher
expression levels of positive regulators such as NIK, CD40,
and LTBR, and lower expression levels of the negative regulators
such as BIRC2/3 (cIAP1/2), which are involved in proteasomal
degradation of NIK (Zarnegar et al., 2008a). These observations
are in line with a previous report on Multiple Myeloma cells (An-
nunziata et al., 2007). In addition to these data, we obtained
convincing evidence for a molecular aspect of NIK accumulation
in ATL cells. Polycomb-dependent epigenetic gene silencing
may be associated with miR-31 loss, followed by NF-kB activa-
tion and other signaling pathways (Figure 7).
DISCUSSION
Constitutive activation of NF-kB contributes to abnormal prolif-
eration and inhibition of apoptotic cell death in cancer cells,ATL Cells
ses revealed tumor-associated deletion of miR-31 region (21/168) and CDKN2
d on CNAG output of the SNP array analysis.
by real-time PCR.
omic loss of the miR-31 region.
out genetic loss in miR-31 region (n = 9, Figure S3B), and normal CD4+ T cells
ion. Arrows represent positions of the motifs. Regions of PCR amplification for
hIP assay (n = 3, mean ± SD). The results of relative enrichment against input
APDH promoters are as positive or negative controls, respectively.
Om1 cells. qRT-PCR (left, n = 3, mean ± SD) and western blotting (right) showed
restoration in TL-Om1 cells (n = 3, mean ± SD). (H) YY1 occupancy in miR-31
reduced by YY1 knockdown. (I) EZH2 occupancy in miR-31 region analyzed by
region.
miR-31 region of primary ATL cells. PBMCs freshly isolated from ATL patients
ormal controls. See also Figure S3.
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Cancer Cell
Epigenetic Loss of miR-31 Activates NF-kBincluding ATL, diffuse large B cell lymphoma (DLBCL), Hodgkin
lymphoma, breast cancer, prostate cancer and others (Prasad
et al., 2010). NF-kB is also essential for various cell functions,
including inflammation, innate immunity, and lymphocytic devel-
opment (Hayden and Ghosh, 2008). Identification of NF-kB
determinants will lead to marked progress in understanding
molecular pathology.
Our global analyses demonstrated an interesting miRNA
expression signature as well as an aberrant mRNA expression
profile, which may be associated with leukemogenesis in the
primary ATL cells (Figures 1 and 6A). We revealed downregula-
tion of tumor-suppressive miRNA including Let-7 family, miR-
125b, and miR-146b, which can contribute to aberrant tumor
cell signaling. Recent studies have suggested unique expression
profiles of miRNAs in ATL (Yeung et al., 2008; Bellon et al., 2009),
but loss ofmiR-31 has not been focused. Cellular amount of miR-
NAs may be susceptible to various environments such as tran-
scriptional activity, maturation processing, and also epigenetic
regulation. The end results appear to be affected by method-
ology employed and conditions and types of samples used.
Our integrated expression profiling of primary ATL cells are
based on a significantly larger number of samples and fruitfully
provides intriguing information that may be useful in improving
the understanding of T cell biology as well as in the identification
of biomarkers for diagnosis.
Pleiotropy of miR-31 was first reported by Valastyan et al.
(2009). The authors elegantly demonstrated the function of
miR-31 in vivo and also identified several target genes that con-
tribute to cell migration and invasiveness. In the present study,
we focused on the functional significance ofmiR-31 in the regula-
tion of NF-kB signaling that contributes to tumor cell survival.
Overexpression of NIK acts as an oncogenic driver in various
cancers. In the present study, NIK was identified as a miR-31
target based on several lines of evidence. First, luciferase-30
UTR reporter assay showed that NIK 30 UTR sequence has
a role for negative regulation (Figure S1B). By combining
a specific inhibitor and mutations in miR-31-binding site, we
demonstrated that miR-31 recognizes and negatively regulates
the NIK 30 UTR (Figures 2A and 2D). Second, by introducing
a miR-31 precursor or inhibitor, we showed that amount of
miR-31 inversely correlates with levels of NIK expression and
downstream signaling (Figures 2E–2K). Third, genetic evidence
indicated strong base pairing and biological conservation
(Bartel, 2009) (Figures S1L–S1O). Our experimental approach
illustrated that mmu-miR-31 regulates mouse Map3k14 gene.
Fourth, individual assessments using gene expression dataFigure 5. Amount of PRC2 Components Epigenetically Links to miR-3
(A) Overexpression of PRC2 components in primary ATL cells measured by qRT-
the data of gene expression microarray (Table S3).
(B) Escalation of EZH2 protein and trimethylated H3K27 levels in primary ATL ce
Resting T cells were as normal control. Scale bars = 20 mm.
(C) Statistical correlation among the levels of miR-31, EZH2, and SUZ12 in individ
graphs.
(D and E) Loss of PCR2 function causes chromatin rearrangement andmiR-31 upr
were established by retroviral vector. The levels of EZH2, SUZ12, Pri-miR-31, a
mean ± SD). (E) Results of ChIP assays with indicated antibodies (n = 3, mean ± SD
GAPDH promoter served as a region control.
(F and G) Knockdown of Polycomb family proteins in MDA-MB-453 cells. (F) EZH
PCR (n = 3, mean ± SD). (G) Histone methylation and EZH2 occupancy evaluate
Cclearly revealed an inverse correlation between the expression
levels of miR-31 and NIK (Figure 3A). Collectively, we provide
definitive evidence for the notion that miR-31 negatively regu-
lates NIK expression and activity.
It is well known that the NIK level directly regulates NF-kB
activity in various cell types (Thu and Richmond, 2010). We
experimentally showed that miR-31 regulates noncanonical
NF-kB activation stimulated by BAFF and CD40L, both of which
are major B cell activating cytokines. Since signals from recep-
tors are essential for the development and activity of B cells,
the negative role of miR-31 in cytokines-induced NIK accumula-
tion appears to be widely important in the noncanonical regula-
tion of NF-kB in B cells and other cell types (Figures 2H–2K).
Again, our findings revealed the role of NIK in the regulation of
canonical NF-kB pathway. Strict regulation of NIK appears to
be closely associated with the fate of lymphocytes.
The level of miR-31 was drastically suppressed in all tested
primary ATL cells, and its magnitude is greater than that which
has been reported in other cancers. Our results demonstrated
a profound downregulation ofmiR-31 (fold change, 0.00403; Fig-
ure 1B) in all ATL cases, suggesting that miR-31 loss is a prereq-
uisite for ATL development. Restoration of miR-31-repressed
NF-kB activity in ATL cells, resulting in impairment of the prolif-
erative index and apoptosis resistance (Figure 3). Furthermore,
our results demonstrate that inhibition of NF-kB promotes tumor
cell death in cell lines and also primary tumor cells from ATL
patients (Figures 3 and 6), which are consistent with our previous
observation (Watanabe et al., 2005). Since it is highly possible
that miR-31 and relevant factors are pivotal in cancers, their
expressions would have a great importance in view of
biomarkers for the aberrant signaling and clinical outcomes.
By studying clinical samples and in vitro and ex vivo models,
we obtained several biologically interesting results. First, we
identified the Polycomb protein complex as a strong suppressor
of miR-31. Generally, the Polycomb group constitutes a multi-
meric complex that negatively controls a large number of genes
involved in cellular development, reproduction, and stemness
(Sparmann and van Lohuizen et al., 2006). However, the key
molecules involved in cancer development, progression, and
prognosis are not yet fully understood. In breast and prostate
cancers, oncogenic functions of EZH2 and NF-kB activation
were reported independently (Kleer et al., 2003; Varambally
et al., 2002; Suh and Rabson, 2004). Interestingly, these tumors
show low miR-31 levels (Valastyan et al., 2009; Schaefer et al.,
2010). Recently, Min et al. (2010) reported that EZH2 activates
NF-kB by silencing the DAB2IP gene in prostate cancer cells.1 Expression in T Cells and Epithelial Cells
PCR (ATL, n = 28; normal, n = 7; mean ± SD). These results were supported by
lls illustrated by immunocytostaining (n = 4, a representative result is shown).
ual ATL samples. Correlation coefficients within ATL samples are shown in the
egulation. (D) TL-Om1 cells expressing shSUZ12, shEZH2, and scrambled RNA
nd mature miR-31 were measured by western blotting and qRT-PCR (n = 3,
). Amounts of immunoprecipitated DNAwere analyzed by region-specific PCR.
2 and SUZ12 are shown by western blot. miR-31 level was examined by qRT-
d by ChIP assay (n = 3, mean ± SD). See also Table S3 and Figure S4.
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Figure 6. Epigenetic Change Driven by Polycomb Group Mediates NF-kB Signaling through miR-31 Regulation
(A) Reciprocal relationship of mRNA expression between NIK and Polycomb group in primary samples. Pearson’s correlation coefficients among ATL samples
are shown.
(B) PRC2 knockdown negatively affects NF-kB signaling in TL-Om1 cells. After establishment of PRC2 knockdown, the levels of NIK RNA (n = 4, mean ± SD) and
proteins of NIK, p52/p100, and phospho-IkBa were examined.
(C) Downregulation of NF-kB activity in PRC2-disrupted cells detected by EMSA.
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Figure 7. Proposed Model for ATL and Other Tumor Cells
Polycomb repressive factors are linked to NIK-dependent NF-kB activation via
miR-31 regulation.
Cancer Cell
Epigenetic Loss of miR-31 Activates NF-kBIn the present study, we found that the Polycomb group regu-
lates miR-31 expression and that elevated expression of EZH2
leads to NF-kB activation via NIK-miR-31 regulation in ATL and
breast cancer cells (Figure 6). We also showed that restoration
of miR-31 partially impaired Polycomb-mediated NF-kB opera-
tion (Figures 6D, 6E, and 6G), suggesting that miR-31 is involved
in this relationship. Furthermore, a connection between NIK and
PRC2 was observed in B cells (Figure 6H). Polycomb group
proteins are essential in lymphocyte development and activation
(Su et al., 2003, 2005). Further, given the NF-kB is a pivotal tran-
scription regulator in normal and oncogenic functions, practical
participations of epigenetic regulators and miR-31 in NF-kB
signaling will increase our understanding of the molecular mech-
anisms of T cell functions. For generalization of the molecular
axis in other cancers and normal cells, further study will be
needed.
Second, YY1 is a recruiter of PRC2 to themiR-31 region. In hu-
mans, the Polycomb response element (PRE) has not been
precisely identified. A good candidate for a mammalian recruiter
of PRC2 is YY1, the homolog of D. melanogaster PHO (Simon
and Kingston, 2009). We found an assembly of the YY1 binding
motif in the miR-31 locus and demonstrated that YY1 knock-
down dislodged EZH2 in this region (Figure 4I), which supports
previous findings (Caretti et al., 2004). The detailed mechanism
by which YY1 mediates recruitment of the Polycomb family
may be important in the context of epigenetic regulation of
orchestrated gene expression and T cell functions.
Third, Polycomb family proteins can control miRNA expres-
sion in an epigenetic fashion. The amount of PRC2 factors
strongly influenced the degree of suppression of miR-31 expres-(D) NF-kB activity evaluated by reporter assays in the presence or absence of m
NF-kB activity in PRC2 knockdowned TL-Om1 cells.
(E) Overexpressed EZH2 activates NF-kB via miR-31. Jurkat cells were transfecte
mean ± SD).
(F) PRC2 dysfunction changes TL-Om1 cell proliferation and response to serum
examined (n = 3, mean ± SD). PRC2 downregulation decreased cell growth with
(G) NF-kB activity in PRC2-knockdowned MDA-MB-453 cells in the presence or
(H) PRC2 disruption inhibits BAFF-dependent NIK accumulation and IkBa phosp
(I) Apoptotic cell death induced by lentivirus-mediated EZH2 knockdown in TL-O
(n = 3) and representative of FACS data are shown.
(J) Summary of primary tumor cell death. Lentivirus-based miR-31 expression, N
samples. Statistical significances are shown in the graph. Results of FACS and q
(K) Expression levels of genes involved in noncanonical NF-kBpathway in primary
tested by qRT-PCR (*p < 0.05). See also Figure S5.
Csion (Figure 5). We speculate that, in addition to controlling the
transcription, the Polycomb group can modulate translation via
miRNA regulation. Furthermore, miR-101 and miR-26a are
known to regulate EZH2 expression (Sander et al., 2008; Varam-
bally et al., 2008), which is supported by our observation
(Figure S4C). This signaling circuit will permit multiple gene
regulation. Whereas genetic loss at themiR-31 locus is observed
in some cases of ATL (Figure 4A), no genetic deletion in the
miR-101-1 or miR-101-2 region was detected in ATL, which is
not consistent with a previous finding in prostate cancer. Our
results also suggested putative association between Let-7 family
and EZH2 (Figure S4). Aberrant downregulations of these miR-
NAs in the primary ATL cells will be the next important questions
to be addressed in efforts to improve understanding of the onco-
genic signaling network.
By collaborative profiling of miRNA andmRNA expression, we
identified a notable relationship between ATL subtypes and
a gene cluster that contains miR-31, NIK, EZH2, and SUZ12.
This finding suggests that an aberrant gene expression pattern
correlates with the malignant phenotype, and this provides
important clues about clinical manifestations and may help
identify therapeutic targets against ATL cells (Figure 6A).
Although HDAC inhibitors did not show effective responses
(Figures S4I and S4J), emerging epigenetic drug such an EZH2
inhibitor (Fiskus et al., 2009) may pave a pathway leading to
cures for various malignancies that involve constitutive activa-
tion of NF-kB.
In summary, we show that genetic and epigenetic loss of
miR-31 is responsible for oncogenic NF-kB activation andmalig-
nant phenotypes in ATL. This provides evidence for the idea that
miR-31 is an important tumor suppressor. An emerging pathway
involving an epigenetic process, miR-31, and NF-kB will provide
a conceptual advance in epigenetic reprogramming, inflamma-
tory signaling, and oncogenic addiction.EXPERIMENTAL PROCEDURES
Cell Lines and Primary ATL Cells
The primary peripheral blood mononuclear cells (PBMCs) from ATL patients
and healthy volunteers used in the present work were a part of those collected
with an informed consent as a collaborative project of the Joint Study on
Prognostic Factors of ATL Development (JSPFAD). The project was approved
by the Institute of Medical Sciences, the University of Tokyo (IMSUT) Human
Genome Research Ethics Committee. Additional ATL clinical samples for
copy number analysis were provided by Drs. Y. Yamada, Nagasaki University,iR-31 inhibitor (n = 5, mean ± SD). Anti-miR-31 treatment partially rescued the
d with an EZH2 plasmid together with miR-31 precursor or control RNA (n = 5,
starvation. Under conditions of 10% or 0.1% of FCS, cell growth curves were
statistical significance.
absence of miR-31 inhibitor were examined (n = 5, mean ± SD).
horylation in BJAB cells.
m1. Venus-positive populations were analyzed by Annexin V/7-AAD stainings
IK knockdown, and EZH2 knockdown showed killing effects in six primary ATL
RT-PCR are shown in Figures S5I and S5J.
ATL cells (ATL, n = 9; normal, n = 7; mean ± SD). Relative expression levels were
ancer Cell 21, 121–135, January 17, 2012 ª2012 Elsevier Inc. 133
Cancer Cell
Epigenetic Loss of miR-31 Activates NF-kBand K. Ohshima, Kurume University, where the projects were approved by the
Research Ethics Committees of Nagasaki University and Kurume University,
respectively. PBMC were isolated by Ficoll separation. ATL cells, primary
lymphocytes, and all T cell lines were maintained in RPMI1640 supplemented
with 10% of FCS and antibiotics. Clinical information of ATL samples is
provided in Table S1.
Expression Analyses
Clinical samples for microarrays were collected by a collaborative study
group, JSPFAD (Iwanaga et al., 2010). Gene expression microarray was
used 4x44K Whole Human Genome Oligo Microarray (Agilent Technologies)
and miRNA microarray was used Human miRNA microarray kit v2 (Agilent
Technologies), respectively. Quantitative RT-PCR was performed with
SYBRGreen (TAKARA). Mature miRNA assays were purchased from Applied
Biosystems.
Copy Number Analyses
Genomic DNA from ATL patients was provided from the material bank of
JSPFAD, Nagasaki University, and Kurume University, and was analyzed by
Affymetrix GeneChip Human Mapping 250K Nsp Array (Affymetrix). Obtained
data were analyzed by CNAG/AsCNAR program (Chen et al., 2008).
Oligonucleotides, Plasmids, and Retrovirus Vectors
All RT-PCR primers and oligonucleotides are described in Supplemental
Experimental Procedures. miRNA precursor and inhibitor were from Applied
Biosystems. Transfection of small RNA and other plasmid DNA were per-
formed by Lipofectamine2000 (Invitrogen). For miRNA or shRNA expression,
retroviral vectors (pSINsi-U6, TAKARA) were used.
30 UTR-Conjugated miR-31 Reporter Assay
HeLa cells were cotransfected with 30 UTR-inserted pMIR-REPORT firefly
plasmid (Ambion), RSV-Renilla luciferase plasmid, and miRNA inhibitor. The
cells were collected at 24 hr posttransfection, and Dual-luciferase reporter
assay was performed (Promega).
Analysis of NF-kB Pathway
NF-kB activity was evaluated by EMSA and reporter assays as previously
described (Horie et al., 2004). Antibodies for western blots are described in
supplemental information. Cell proliferative assay was performed by Cell
Counting Kit-8 (Dojindo).
Lentivirus Vectors and Apoptosis Analysis
A lentivirus vector (CS-H1-EVBsd) was provided from RIKEN, BRC, Japan.
Lentivirus solution was produced by cotransfection with packaging plasmid
(pCAG-HIVgp) and VSV-G- and Rev-expressing plasmid (pCMV-VSV-G-
RSV-Rev) into 293FT cells. After infection of lentivirus, the apoptotic cell was
evaluated by PE Annexin V / 7-AAD staining (BD PharMingen) and analyzed
by FACS Calibur (Becton, Dickinson). Collected data were analyzed by FlowJo
software (Tree Star).
ChIP Assay
ChIP assay was previously described (Yamagishi et al., 2009). Briefly, cells
were crosslinked with 1% of formaldehyde, sonicated, and subjected to chro-
matin-conjugated IP using specific antibodies. Precipitated DNA was purified
and analyzed by real-time PCRwith specific primers (see Supplemental Exper-
imental Procedures).
Computational Prediction
To identify miR-31 target genes, we integrated the output results of multiple
prediction programs; TargetScan, PicTar, miRanda, and PITA. RNAhybrid
was for secondary structure of miRNA-30 UTR hybrid. TSSG program was
for TATA box and TSS predictions. DNA methylation site was predicted by
CpG island Searcher.
Statistical Analyses
Data were analyzed as follows: (1) Welch’s t test for Gene Expression Micro-
array (p value cutoff at 106) and miRNA Microarray (p value cutoff at 105);
(2) Pearson’s correlation for two-dimensional hierarchical clustering analysis134 Cancer Cell 21, 121–135, January 17, 2012 ª2012 Elsevier Inc.and individual assessment of microarray data sets; (3) two-tailed pared
Student’s t test with p < 0.05 considered statistically significant for in vitro
cell lines and primary cells experiments, including luciferase assay, RT-PCR,
ChIP assay, cell growth assay, and migration assay. Data are presented as
mean ± SD.
ACCESSION NUMBERS
Coordinates have been deposited in Gene Expression Omnibus database
with accession numbers, GSE31629 (miRNA microarray), GSE33615 (gene
expression microarray), and GSE33602 (copy number analyses).
SUPPLEMENTAL INFORMATION
Supplemental Information includes three tables, five figures, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2011.12.015.
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